StockData
Alto Neuroscience, Inc. logo

Alto Neuroscience, Inc. (ANRO) shareholders

ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$24.91−2.21 (-8.15%)

Close on Nov 17, 2026Market cap $977.52MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
75.1%
29M of 39M shares
Institutional holders
114
27 new, 22 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 3 sales
Net sold $3.57M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Perceptive Advisors LLC
Joint filing with Joseph Edelman (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%)
4,176,7119.99%13G (passive) amendmentJun 30, 2026
Alpha Wave Ventures GP, Ltd
Joint filing with Alpha Wave Global, LP (13.80%), Chimera Investment LLC (13.80%) and 1 more
3,707,75713.80%13G (passive)Feb 6, 2024
Robert Egen Atkinson
Joint filing with Commodore Capital LP (9.90%), Commodore Capital Master LP (9.90%) and 1 more
3,588,1809.90%13G (passive) amendmentMar 31, 2026
Joseph Edelman
Joint filing with Perceptive Advisors LLC (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%)
3,249,9349.99%13G (passive) amendmentDec 31, 2025
Commodore Capital Master LP
Joint filing with Commodore Capital LP (9.90%), Robert Egen Atkinson (9.90%) and 1 more
3,245,6289.90%13G (passive) amendmentDec 31, 2025
Commodore Capital LP
Joint filing with Commodore Capital Master LP (9.80%), Robert Egen Atkinson (9.80%) and 1 more
3,190,2679.80%13G (passive)Oct 20, 2025
EcoR1 Capital, LLC
Joint filing with Oleg Nodelman (5.80%), EcoR1 Capital Fund Qualified, L.P. (5.30%)
2,232,0005.80%13G (passive)Jul 13, 2026
Alex Silverstein
Joint filing with Sirenia Capital Management LP (6.20%)
2,219,5686.20%13G (passive) amendmentJun 30, 2026
BlackRock, Inc.2,104,4066.00%13G (passive)Jun 30, 2026
Perceptive Life Sciences Master Fund, Ltd.
Joint filing with Perceptive Advisors LLC (7.30%), Joseph Edelman (7.30%)
1,989,3937.30%13G (passive)Oct 3, 2025
Vanguard Capital Management1,970,1085.02%13G (passive)Sep 30, 2026
Armistice Capital, LLC
Joint filing with Steven Boyd (6.00%)
1,624,0006.00%13G (passive) amendmentDec 31, 2025
Parag Shah
Joint filing with K2 HealthVentures Equity Trust LLC (5.60%), Anup Arora (5.60%)
1,617,8555.60%13G (passive)Jan 13, 2025
Amit Etkin1,461,1305.40%13G (passive)Sep 30, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ANROValueChange% of portfolio
Alpha Wave Global, LP3,707,7579.45%$97.85M–1.57%
Commodore Capital LP2,723,1966.94%$71.87M–4.28%
BlackRock, Inc.2,121,0095.40%$55.97M+1,454,8210.00%
Perceptive Advisors LLC1,609,8934.10%$42.49M−400,0000.64%
Adage Capital Partners Gp, L.L.C.1,600,0004.08%$42.22M+1,215,0000.06%
Vanguard Capital Management LLC1,389,4773.54%$36.67M+182,4520.00%
Spruce Street Capital LP1,353,0473.45%$35.71M+27,8377.01%
Vivo Capital, LLC1,208,8583.08%$31.90M+173,3072.91%
Franklin Resources Inc1,013,3072.58%$26.74M−88,5670.01%
Armistice Capital, LLC864,0002.20%$22.80M−48,0000.28%
Affinity Asset Advisors, LLC850,0002.17%$22.43M+350,0001.01%
Vestal Point Capital, LP785,0002.00%$20.72M−1,279,0750.48%
State Street Corp685,9451.75%$18.10M+486,4420.00%
Geode Capital Management, LLC678,1991.73%$17.90M+385,3000.00%
72 Investment Holdings, LLC667,7781.70%$17.62M–35.27%
Northern Trust Corp632,7011.61%$16.70M+159,2980.00%
Millennium Management LLC558,3201.42%$14.73M−263,6620.01%
Point72 Asset Management, L.P.502,9501.28%$13.27M−1370.01%
Integral Health Asset Management, LLC500,0001.27%$13.20M–0.52%
VR Adviser, LLC500,0001.27%$13.20M–0.40%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202611429M75.1%27 / 3927 / 226M4M
Q1 202611027M68.4%25 / 2743 / 107M4M
Q4 20259724M62.4%30 / 2725 / 99M2M
Q3 20257717M43.2%9 / 1926 / 121M1M
Q2 20258017M44.1%20 / 2123 / 232M5M
Q1 20258321M53.1%20 / 1827 / 122M3M
Q4 20247723M57.4%24 / 3110 / 227M8M
Q3 20247523M58.5%23 / 359 / 56M1M
Q2 20245819M47.4%18 / 2012 / 133M1M
Q1 20245316M40.9%53 / 00 / 016M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

84 funds held ANRO in Q2 2026, 69% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ANROValue% of fundAs of
Vanguard Total Stock Market Index Fund1,011,8812.58%$26.70M0.00%Jun 30, 2026
iShares Russell 2000 ETF663,3521.69%$17.51M0.02%Jun 30, 2026
Vanguard Extended Market Index Fund346,6180.88%$9.15M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund287,0330.73%$7.77M0.02%Jul 31, 2026
iShares Russell 2000 Growth ETF240,4040.61%$6.34M0.04%Jun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.228,0570.58%$6.02M0.05%Jun 30, 2026
iShares Biotechnology ETF221,5130.56%$5.85M0.06%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF190,2030.48%$5.02M1.17%Jun 30, 2026
Franklin Biotechnology Discovery Fund182,8340.47%$4.95M0.43%Jul 31, 2026
Franklin Biotechnology Discovery Fund165,0700.42%$4.47M0.39%Jul 31, 2026
Fidelity Extended Market Index Fund138,1810.35%$2.77M0.01%May 31, 2026
iShares Micro-Cap ETF88,0480.22%$2.32M0.15%Jun 30, 2026
AdvisorShares Psychedelics ETF70,7480.18%$1.87M4.20%Jun 30, 2026
Schwab Small-Cap Index Fund63,5700.16%$1.72M0.02%Jul 31, 2026
Master Small Cap Index Series48,9590.12%$1.29M0.02%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Amit EtkinPRESIDENT AND CEO, Director833,9492.13%May 15, 2026
Nicholas Conrad SmithPRESIDENT AND CFO79,0600.20%Oct 5, 2026
Adam SavitzCHIEF MEDICAL OFFICER39,8510.10%Feb 13, 2026
Jr. Michael Conick HanleyCHIEF OPERATING OFFICER––Feb 13, 2026
Andrew Craig MillerDirector––May 29, 2026
Gwill YorkDirector23,9170.06%May 14, 2026
Christopher Nixon CoxDirector588,8981.50%May 14, 2026
Andrew DreyfusDirector––May 14, 2026
Husseini ManjiDirector––May 14, 2026
Ramiro SanchezDirector––May 14, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Nicholas Conrad Smith
PRESIDENT AND CFO
Oct 2, 2026Option exercise+55,000$2.32$127.60K79,060
Nicholas Conrad Smith
PRESIDENT AND CFO
Sep 30, 2026Sale(10b5-1 plan)−886$26.87$23.81K24,060
Nicholas Conrad Smith
PRESIDENT AND CFO
Sep 30, 2026Sale(10b5-1 plan)−23,170$25.78$597.29K24,946
Nicholas Conrad Smith
PRESIDENT AND CFO
Sep 30, 2026Option exercise+24,056$2.35$56.53K48,116
Nicholas Conrad Smith
PRESIDENT AND CFO
Sep 29, 2026Sale(10b5-1 plan)−110,830$26.58$2.95M24,060
Nicholas Conrad Smith
PRESIDENT AND CFO
Sep 29, 2026Option exercise+54,375$2.35$127.78K134,890
Nicholas Conrad Smith
PRESIDENT AND CFO
Sep 29, 2026Option exercise+56,455$2.35$132.67K80,515
Amit Etkin
PRESIDENT AND CEO, Director
May 14, 2026Gift−400,000––833,949
Nicholas Conrad Smith
CHIEF FINANCIAL OFFICER & CBO
Mar 1, 2026Tax withholding−2,806$19.69$55.25K24,060
Amit Etkin
PRESIDENT AND CEO, Director
Mar 1, 2026Tax withholding−6,227$19.69$122.61K1,233,949
Adam Savitz
CHIEF MEDICAL OFFICER
Jul 10, 2024Buy+2,931$13.22$38.75K39,851
Adam Savitz
CHIEF MEDICAL OFFICER
Jul 9, 2024Buy+1,388$13.15$18.25K36,920
Adam Savitz
CHIEF MEDICAL OFFICER
Jul 9, 2024Buy+10,681$12.53$133.83K35,532
Nicholas Conrad Smith
CHIEF FINANCIAL OFFICER
Mar 28, 2024Buy+4,550$16.56$75.35K26,866
Nicholas Conrad Smith
CHIEF FINANCIAL OFFICER
Mar 28, 2024Buy+1,600$15.80$25.28K22,316
Nicholas Conrad Smith
CHIEF FINANCIAL OFFICER
Mar 1, 2024Award+19,153––20,716
Amit Etkin
PRESIDENT AND CEO, Director
Mar 1, 2024Award+34,711––1,240,176
Investment Group Ltd. Apeiron
–
Feb 6, 2024Conversion+251,881––251,881
Investment Group Ltd. Apeiron
–
Feb 6, 2024Conversion+674,658––674,658
Alpha Wave Global, LP
10% owner
Feb 6, 2024Conversion+1,962,995––1,962,995
Alpha Wave Global, LP
10% owner
Feb 6, 2024Conversion+1,144,762––3,107,757
Alpha Wave Global, LP
10% owner
Feb 6, 2024Buy+600,000$16.00$9.60M3,707,757
Adam Savitz
CHIEF MEDICAL OFFICER
Feb 6, 2024Conversion+7,851––7,851
Adam Savitz
CHIEF MEDICAL OFFICER
Feb 6, 2024Buy+17,000$16.00$272.00K24,851
Gwill York
Director
Feb 6, 2024Conversion+23,917––23,917
Po Yu (Jeff) Chen
Director
Feb 6, 2024Conversion+39,259––39,259
Po Yu (Jeff) Chen
Director
Feb 6, 2024Conversion+8,450––47,709
Amit Etkin
PRESIDENT AND CEO, Director
Feb 6, 2024Conversion+11,777––1,202,340
Amit Etkin
PRESIDENT AND CEO, Director
Feb 6, 2024Buy+3,125$16.00$50.00K1,205,465
Christopher Nixon Cox
Director
Feb 6, 2024Conversion+588,898––588,898
Christopher Nixon Cox
Director
Feb 6, 2024Conversion+126,755––715,653
Nicholas Conrad Smith
CHIEF FINANCIAL OFFICER
Feb 6, 2024Buy+1,563$16.00$25.01K1,563

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
15.08%
6M shares short
Days to cover
10.5
At 1M shares a day
Change since last report
+9.2%
From 5M shares
Short volume, 20 days
63.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Alto Neuroscience's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,994 shares on Aug 24, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Nicholas Conrad Smith
Officer
Sep 29, 2026134,886$3.60MSep 29, 2026Exercise of Stock Options

See a number that looks wrong?